Home › Compare › NVNOW vs JNJ

NVNOW vs JNJ: Dividend Comparison 2026

NVNOW yields 31746.03% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NVNOW wins by $5.185613516568806e+21M in total portfolio value
10 years
NVNOW
NVNOW
● Live price
31746.03%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.185613516568806e+21M
Annual income
$5,153,678,609,075,543,000,000,000,000.00
Full NVNOW calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — NVNOW vs JNJ

📍 NVNOW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNVNOWJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NVNOW + JNJ cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
NVNOW pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NVNOW
Annual income on $10K today (after 15% tax)
$2,698,412.70/yr
After 10yr DRIP, annual income (after tax)
$4,380,626,817,714,211,500,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, NVNOW beats the other by $4,380,626,817,714,211,500,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NVNOW + JNJ for your $10,000?

NVNOW: 50%JNJ: 50%
100% JNJ50/50100% NVNOW
Portfolio after 10yr
$2.592806758284403e+21M
Annual income
$2,576,839,304,537,771,700,000,000,000.00/yr
Blended yield
99.38%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

NVNOW
No analyst data
Altman Z
8.8
Piotroski
2/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NVNOW buys
0
JNJ buys
0
No recent congressional trades found for NVNOW or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNVNOWJNJ
Forward yield31746.03% ✓3.36%
Annual dividend / share$2.00$4.96 ✓
Payout ratio50% ✓55%
1-year div growth0%4.2% ✓
5-year div CAGR0%5.8% ✓
Portfolio after 10y$5.185613516568806e+21M$20.0K ✓
Annual income after 10y$5,153,678,609,075,543,000,000,000,000.00 ✓$827.78
Total dividends collected$5.183513017945435e+21M$5.6K ✓
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: NVNOW vs JNJ ($10,000, DRIP)

YearNVNOW PortfolioNVNOW Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$3,185,303$3,174,603.17$10,676$355.77+$3.17M → NVNOW
2$948,461,879$945,053,604.69$11,407$389.39+$948.45M → NVNOW
3$264,006,389,920$262,991,535,709.23$12,198$426.53+$264006.38M → NVNOW
4$68,697,679,083,941$68,415,192,246,726.70$13,056$467.62+$68697679.07M → NVNOW
5$16,711,325,707,704,242$16,637,819,191,084,424.00$13,987$513.12+$16711325707.69M → NVNOW
6$3,800,403,109,124,150,000$3,782,521,990,616,906,000.00$14,998$563.56+$3800403109124.13M → NVNOW
7$807,993,116,765,802,000,000$803,926,685,439,039,000,000.00$16,098$619.52+$807993116765802.00M → NVNOW
8$160,603,443,082,694,730,000,000$159,738,890,447,755,300,000,000.00$17,295$681.69+$160603443082694720.00M → NVNOW
9$29,845,707,937,629,030,000,000,000$29,673,862,253,530,545,000,000,000.00$18,599$750.82+$29845707937629028352.00M → NVNOW
10$5,185,613,516,568,806,000,000,000,000$5,153,678,609,075,543,000,000,000,000.00$20,022$827.78+$5.185613516568806e+21M → NVNOW

NVNOW vs JNJ: Complete Analysis 2026

NVNOW — Stock

enVVeno Medical Corporation, a medical device company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the treatment of severe deep venous chronic venous insufficiency. Its VenoValve is implanted in the femoral vein and acts as a one-way valve to help restore proper blood flow in the leg. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.

Full NVNOW Calculator →

JNJ — Healthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this NVNOW vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NVNOW vs SCHDNVNOW vs JEPINVNOW vs ONVNOW vs KONVNOW vs MAINNVNOW vs ABBVNVNOW vs MRKNVNOW vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.